[go: up one dir, main page]

CO4940415A1 - CHEMICAL COMPOUND - Google Patents

CHEMICAL COMPOUND

Info

Publication number
CO4940415A1
CO4940415A1 CO98011404A CO98011404A CO4940415A1 CO 4940415 A1 CO4940415 A1 CO 4940415A1 CO 98011404 A CO98011404 A CO 98011404A CO 98011404 A CO98011404 A CO 98011404A CO 4940415 A1 CO4940415 A1 CO 4940415A1
Authority
CO
Colombia
Prior art keywords
chemical compound
sodium salt
hydrated form
crystalline hydrated
phenylpiro
Prior art date
Application number
CO98011404A
Other languages
Spanish (es)
Inventor
Cimarosti Zadeo
Paolo Maragni
Original Assignee
Glaxo Wellcome Spa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxo Wellcome Spa filed Critical Glaxo Wellcome Spa
Publication of CO4940415A1 publication Critical patent/CO4940415A1/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/06Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/04Centrally acting analgesics, e.g. opioids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Neurology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biomedical Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Neurosurgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Pyrrole Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Indole Compounds (AREA)

Abstract

La sal de sodio del ácido (E) 4,6-dicloro-3-(2-oxo-1-fenilpirro-lidin-3-ilideno metil)-1H-indol-2-carboxílico, en una forma hidratada cristalina.Un proceso para la preparación de una forma hidratada cristalina como se define en cualesquiera de las reivindicaciones 1 a 4, caracterizado porque comprende la cristalización de la sal de sodio a partir de una solución de un alcanol acuosos".The sodium salt of (E) 4,6-dichloro-3- (2-oxo-1-phenylpiro-lidin-3-ylidene methyl) -1H-indole-2-carboxylic acid, in a crystalline hydrated form. for the preparation of a crystalline hydrated form as defined in any one of claims 1 to 4, characterized in that it comprises the crystallization of the sodium salt from a solution of an aqueous alkanol ".

CO98011404A 1997-03-05 1998-03-03 CHEMICAL COMPOUND CO4940415A1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB9704498.6A GB9704498D0 (en) 1997-03-05 1997-03-05 Chemical compound

Publications (1)

Publication Number Publication Date
CO4940415A1 true CO4940415A1 (en) 2000-07-24

Family

ID=10808697

Family Applications (1)

Application Number Title Priority Date Filing Date
CO98011404A CO4940415A1 (en) 1997-03-05 1998-03-03 CHEMICAL COMPOUND

Country Status (29)

Country Link
EP (1) EP0966463A1 (en)
JP (1) JP2001513796A (en)
KR (1) KR20000075907A (en)
CN (1) CN1249750A (en)
AP (1) AP9901637A0 (en)
AR (1) AR011178A1 (en)
AU (1) AU6825198A (en)
BG (1) BG103779A (en)
BR (1) BR9808305A (en)
CA (1) CA2282851A1 (en)
CO (1) CO4940415A1 (en)
EA (1) EA199900710A1 (en)
EE (1) EE9900387A (en)
GB (1) GB9704498D0 (en)
HR (1) HRP980114A2 (en)
HU (1) HUP0002109A2 (en)
ID (1) ID24207A (en)
IL (1) IL131489A0 (en)
IS (1) IS5166A (en)
NO (1) NO994303L (en)
NZ (1) NZ337315A (en)
OA (1) OA11154A (en)
PE (1) PE51399A1 (en)
PL (1) PL335652A1 (en)
SK (1) SK119699A3 (en)
TR (1) TR199902117T2 (en)
WO (1) WO1998039327A1 (en)
YU (1) YU43499A (en)
ZA (1) ZA981791B (en)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9704499D0 (en) * 1997-03-05 1997-04-23 Glaxo Wellcome Spa Method of manufacture
GB9825988D0 (en) 1998-11-27 1999-01-20 Pfizer Ltd Indole derivatives
GB9915231D0 (en) 1999-06-29 1999-09-01 Pfizer Ltd Pharmaceutical complex
US9737531B2 (en) 2012-07-12 2017-08-22 Glytech, Llc Composition and method for treatment of depression and psychosis in humans
AU2018284335A1 (en) 2017-06-12 2020-01-30 Glytech Llc. Treatment of depression with NMDA antagonists and D2/5HT2A or selective 5HT2A antagonists

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9321221D0 (en) * 1993-10-14 1993-12-01 Glaxo Spa Heterocyclic compounds

Also Published As

Publication number Publication date
NZ337315A (en) 2001-02-23
SK119699A3 (en) 2000-05-16
YU43499A (en) 2000-12-28
PL335652A1 (en) 2000-05-08
PE51399A1 (en) 1999-06-07
WO1998039327A1 (en) 1998-09-11
NO994303L (en) 1999-11-03
EE9900387A (en) 2000-04-17
IS5166A (en) 1999-08-27
CA2282851A1 (en) 1998-09-11
HUP0002109A2 (en) 2001-04-28
TR199902117T2 (en) 2000-03-21
AU6825198A (en) 1998-09-22
BG103779A (en) 2000-06-30
KR20000075907A (en) 2000-12-26
GB9704498D0 (en) 1997-04-23
OA11154A (en) 2003-04-16
NO994303D0 (en) 1999-09-03
EA199900710A1 (en) 2000-04-24
IL131489A0 (en) 2001-01-28
ZA981791B (en) 1999-09-03
AP9901637A0 (en) 1999-09-30
JP2001513796A (en) 2001-09-04
EP0966463A1 (en) 1999-12-29
HRP980114A2 (en) 1998-12-31
ID24207A (en) 2000-07-13
BR9808305A (en) 2000-05-16
AR011178A1 (en) 2000-08-02
CN1249750A (en) 2000-04-05

Similar Documents

Publication Publication Date Title
AR061765A2 (en) PROCESS FOR THE PREPARATION OF PRAVASTATIN SODIUM SALT IN A CRYSTAL FORM
FI20002767A0 (en) Iodine salts as latent acid donors
PT1177176E (en) DERIVATIVES OF TRIARILIC ACIDS AS LIGANDS OF PPAR RECEPTORS.
AR043266A2 (en) CRYSTAL FORM OF THE MONOMETANSULPHONIC ACID ADDITION SALT OF A N-PHENYL-2-PYRIMIDINAMINE DERIVATIVE
GT199900055A (en) NEW DIETHYDROPYRIMIDINES2 HETEROCYCLICALLY SUBSTITUTED.
GT199900199A (en) COMPOSITIONS OF HIGHLY CONCENTRATED Aqueous GLISOPHATE.
DK1163207T3 (en) Improved process for the preparation of non-hygroscopic salts of L (-) - carnitine
DE60334678D1 (en) ANTIBODY-CONTAINING PHARMACEUTICAL SOLUTIONS
ATE526022T1 (en) STABILIZED COMPOSITIONS CONTAINING BENZIMIDAZOLES
CO5580776A2 (en) STABLE PHARMACEUTICAL FORMULATION IN SOLUTION OF OXALIPLATIN
PT1252170E (en) SELECTIVE CRYSTALLIZATION OF SODIUM 3-PYRIDYL-1-HYDROXYETHYDIDENE-1,1-BISPHOSPHONIC ACID AS HEMIPENTAHYDRATE OR MONOHYDRATE
NO20034393L (en) Double feeding system for solid-state chemical
ES2187261B2 (en) ETERES AND AMIDAS COMPOUNDS AND THEIR PREPARATION, AS ANTI-DIABETIC AGENTS.
DK0797426T3 (en) Formation of stable aqueous solutions of tin compounds
NO964121D0 (en) Pyrimidine or triazine carboxylic acid derivatives for use as drugs
CO4940415A1 (en) CHEMICAL COMPOUND
PT828721E (en) 2-AMINO-BENXOXAZINONES FOR THE TREATMENT OF VIRAL INFECTIONS
ATE181957T1 (en) PASTE CLEANING AGENT
EA200101150A1 (en) PRUNCTIONAL SOLUTION FOR ORAL APPLICATION
ES2075454T3 (en) PURE CRYSTALLINE FORM OF RIFAPENTINE.
TR200001121T2 (en) Antirheumatic substance.
ITBO990621A0 (en) CIGAR FEEDING UNIT.
DK1239935T3 (en) Anti-foaming agent and its use
BR0107483A (en) Process for the preparation of a compound
ES2183649T3 (en) METHOD FOR MANUFACTURING FORMAT OF AN ALKALINE METAL OR OF AN ALKALINOTERAL METAL.